'MEI Pharma and Infinity Pharmaceuticals announce definitive merger agreement to advance three promising clinical oncology candidates',
'Monopar and NorthStar announce expanded radiopharma program, positive preclinical results, and visibility toward human trials',
'SonoThera receives exclusive licensing of GE HealthCare’s Optison and Sonazoid Microbubble products for use with its ultrasound-guided gene therapy platform',
'Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy',
'Rhythm Pharmaceuticals announces acquisition of Xinvento B.V. and portfolio of investigational therapeutics',
'Adamis Pharmaceuticals and DMK Pharmaceuticals announce agreement and plan of merger',
'Tempus announces new strategic collaboration with Pfizer to advance oncology therapeutic development',
'Landos Biopharma announces transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ founder',
'Oragenics enters into an exclusive global license agreement with Inspirevax to develop intranasal covid vaccine candidate',
'ImmunoGen announces a global, multi-target license and option agreement with Vertex for the use of ImmunoGen's ADC technology in the development of novel targeted conditioning agents',
'Intract Pharma and Elasmogen announce collaboration to discover and develop novel, orally-delivered protein therapeutics',
'Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor',
'Intract Pharma and NIBEC enter into an agreement to develop a novel oral peptide therapy for treatment of ulcerative colitis.',
'SiSaf and the University of Leipzig partner to develop Bio-Courier targeted miRNA for the treatment of pancreatic cancer',
'Intract Pharma and Celltrion Group announce collaboration for development of oral Infliximab',
'Elasmogen and Intract enter license agreement for Soteria and Phloral technologies',
'Intract Pharma and N&S Pharmacy Investment announce partnership to develop orally-delivered GLP-1R agonist peptide therapeutic',
'Intract Pharma and NIBEC enter into an agreement to develop a novel oral peptide therapy for treatment of ulcerative colitis.',
'ResolutionRx and RespireRx Pharmaceuticals announce ResolutionRx’s entry into a services agreement with iNGENu CRO',
'Flamingo Therapeutics and Dynacure announce merger to create leading RNA therapeutics company focused on clinical oncology',